Medtech company 3Spine completed enrollment for its FDA clinical trial on the Motus device, according to a Jan. 10 news release.
Last year 3Spine completed 325 surgeries — 151 were done as part of the Motus study and 174 real-world posterior lumbar fusions. The FDA clinical trial spans across 14 states and includes patients from 23 to 79.
Motus is an alternative to spinal fusion. It earned FDA breakthrough device designation in 2020.